while i agree with sokol's comments (wish i've had that advice a few years back), just for george's comment, drug cost of $3K per year seems like really going for market share, if 2-73 is really approved.
maybe when/if 2-73 is approved, other drugs in addition to non amyloid clearing mabs could be on the market with combination therapies being looked into
News 
Market Data 
Discover 
